Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD (NCT07461532) | Clinical Trial Compass
RecruitingNot Applicable
Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD
China20 participantsStarted 2026-04-01
Plain-language summary
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.
✓. Portal hypertension bleeding .
✓. Splenomegaly with secondary hypersplenism.
✓. No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.
✓. Underwent laparoscopic splenectomy at our center.
✓. Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3.
✓. subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3
✓. Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3.
Exclusion criteria
✕. Hepatocellular carcinoma or any other malignancy.
✕. Hypercoagulable state other than the liver disease related.
✕. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.
✕. Child - Pugh C
✕. Recent peptic ulcer disease
What they're measuring
1
Proportion of complete recanalization of portal vein thrombosis